Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy

Elias Jabbour, MD, Koji Sasaki, Naval Daver, Naveen Pemmaraju, MD, Nitin Jain, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD, Gautam Borthakur, MD, Marina Konopleva, MD PhD, Stefan H. Faderl, MD, Susan O'Brien, MD, Jorge Cortes, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 534.

https://doi.org/10.1182/blood.V124.21.534.534

Published: 2014

Journal Articles

Bone Marrow May Be More Informative Than Peripheral Blood To Evaluate Minimal Residual Disease During 1st and 2nd Year Follow Up After First-Line Fludarabine, Cyclophosphamide, and Rituximab For Chronic Lymphocytic Leukemia

Paolo Strati, MD, Michael J. Keating, MD, Susan O'Brien, MD, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Zeev Estrov, MD, Jeffrey L. Jorgensen, MD, Stefan H. Faderl, MD, William G. Wierda, MD, PhD

Blood (2013) 122 (21): 1621.

https://doi.org/10.1182/blood.V122.21.1621.1621

Published: 2013

Journal Articles

Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Elias Jabbour, MD, Hagop Kantarjian, Deborah A. Thomas, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Stefan H. Faderl, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Rebecca Garris, BSc, Prescott Hillary, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, William G. Wierda, MD, Susan O'Brien, MD

Blood (2013) 122 (21): 2663.

https://doi.org/10.1182/blood.V122.21.2663.2663

Published: 2013

Journal Articles

Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

Elias Jabbour, MD, Kantarjian Hagop, MD, Deborah Thomas, MD, Guillermo Garcia-Manero, MD, Daniela Hoehn, MD, PhD, Rebecca Garris, BSc, Stefan H. Faderl, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Susan O'Brien, MD

Blood (2013) 122 (21): 2664.

https://doi.org/10.1182/blood.V122.21.2664.2664

Published: 2013

Journal Articles

Incidence, Clinical Characteristics, and Prognostic Relevance Of Clonal T-Cell Receptor Positive (TCR + ) Populations In Patients With Myelodysplastic Syndrome (MDS)

Preetesh Jain, MD, DM, PhD, Hagop Kantarjian, MD, Keyur P. Patel, MD, PhD, Elias Jabbour, MD, Naval Daver, MD, Sherry Pierce, Ohad Benjamini, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD, Stefan H. Faderl, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD

Blood (2013) 122 (21): 5231.

https://doi.org/10.1182/blood.V122.21.5231.5231

Published: 2013

Journal Articles

Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy

Aziz Nazha, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Courtney D. DiNardo, MD, Darla Miller, Stefan H. Faderl, MD

Blood (2013) 122 (21): 1525.

https://doi.org/10.1182/blood.V122.21.1525.1525

Published: 2013

Journal Articles

Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL)

Michael E. Rytting, MD, Deborah A. Thomas, MD, Susan O'Brien, MD, Kurt Schroeder, RN, Rebecca Garris, BSc, Jorge E. Cortes, MD, Farhad Ravandi, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Stefan H. Faderl, MD, Anna R. K. Franklin, MD, Gautam Borthakur, MBBS, Steven M. Kornblau, MD, Hagop M. Kantarjian, MD

Blood (2013) 122 (21): 1400.

https://doi.org/10.1182/blood.V122.21.1400.1400

Published: 2013

Journal Articles

Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation

Ohad Benjamini, MD, Uri Rozovski, MD, Preetesh Jain, MD, DM, PhD, William G. Wierda, MD, Susan O'Brien, MD, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Stefan H. Faderl, MD, Elizabeth J Shpall, MD, Chitra M Hosing, MD, Issa F. Khouri, MD, Richard E Champlin, MD, Michael J. Keating, MD, Zeev Estrov, MD

Blood (2013) 122 (21): 2880.

https://doi.org/10.1182/blood.V122.21.2880.2880

Published: 2013

Journal Articles

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Farhad Ravandi, MD, Susan O'Brien, MD, Rebecca Garris, BSc, Stefan H. Faderl, MD, Deborah A. Thomas, MD, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD

Blood (2013) 122 (21): 3914.

https://doi.org/10.1182/blood.V122.21.3914.3914

Published: 2013

Journal Articles

Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience

Preetesh Jain, MD, DM, PhD, Hagop M Kantarjian, MD, Jorge E. Cortes, MD, Elias J. Jabbour, MD, Stefan H. Faderl, MD, William G. Wierda, MD, PhD, Guillermo Garcia-Manero, MD, Alessandra Ferrajoli, MD, Srdan Verstovsek, MD, PhD, Jan A. Burger, MD, PhD, Luis Fayad, MD, Jorge Romaguera, MD, Rebecca Garris, BSc, Farhad Ravandi, MD, Susan O'Brien, MD, Deborah Thomas, MD

Blood (2013) 122 (21): 3917.

https://doi.org/10.1182/blood.V122.21.3917.3917

Published: 2013

Journal Articles

A Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, In Patients With Advanced Leukemias

Marina Konopleva, MD, PhD, Damian R Handisides, Mary Ann Richie, RN, Juliana M Benito, PhD, Gautam Borthakur, MD, Elias J. Jabbour, MD, Stefan H. Faderl, MD, Jorge E. Cortes, MD, Stewart Kroll, Michael Andreeff, MD, PhD, Hagop M Kantarjian, MD, Deborah A. Thomas, MD

Blood (2013) 122 (21): 3920.

https://doi.org/10.1182/blood.V122.21.3920.3920

Published: 2013

Journal Articles

Final Report Of Phase II Study Of Sorafenib and 5-Azacytidine In Patients With Relapsed Or Untreated Acute Myeloid Leukemia and FLT3 -ITD mutation

Maro Ohanian, DO, Mark Levis, MD, PhD, Stefan H. Faderl, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Naval G. Daver, MD, Sara E Dellasala, RN, Sherry Pierce, Jan A. Burger, MD, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2013) 122 (21): 3934.

https://doi.org/10.1182/blood.V122.21.3934.3934

Published: 2013

Journal Articles

Incidence Of and Risk Factors For Acute Myeloid Leukemia Involvement Of The Central Nervous System

Rozovski Uri, MD, Maro Ohanian, DO, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Stefan H. Faderl, MD, Jorge E. Cortes, MD, Sherry R. Pierce, RN, BS, Kantarjian Hagop, MD, Zeev Estrov, MD

Blood (2013) 122 (21): 3883.

https://doi.org/10.1182/blood.V122.21.3883.3883

Published: 2013

Journal Articles

Signal Transducer and Activator Of Transcription 3 Activates and Deregulates Micro RNA Expression In Chronic Lymphocytic Leukemia Cells

Rozovski Uri, MD, George Calin, MD PhD, Tetsoro Setoyama, Abundu Lucilla, Harris David, Ping Li, PhD, Lui Zhiming, Grugurevic Srdana, Alessandra Ferrajoli, MD, Stefan H. Faderl, MD, Jan A. Burger, MD, PhD, Susan O'Brien, MD, William G. Wierda, MD, PhD, Michael J. Keating, MD, Zeev Estrov, MD

Blood (2013) 122 (21): 4152.

https://doi.org/10.1182/blood.V122.21.4152.4152

Published: 2013

Journal Articles

Symptom Burden In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Loretta A. Williams, PhD, RN, Patricia S. Ault, MS, ACNP, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Alfonso Quintas-Cardama, MD, Gautam Borthakur, MD, Stefan H. Faderl, MD, Elias J. Jabbour, MD, Charles S. Cleeland, PhD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2988.

https://doi.org/10.1182/blood.V122.21.2988.2988

Published: 2013

Journal Articles

Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy

Aziz Nazha, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD, Courtney D. DiNardo, MD, Gautam Borthakur, MD, Naval G. Daver, MD, Stefan H. Faderl, MD, Jing Ning, Wei Qiao, Farhad Ravandi, MD, Tapan M. Kadia, MD, Sherry R. Pierce, RN, BS, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD

Blood (2013) 122 (21): 2788.

https://doi.org/10.1182/blood.V122.21.2788.2788

Published: 2013

Journal Articles

Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)

Aziz Nazha, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Huang Xuelin, Sangbum Choi, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Marina Konopleva, MD, PhD, Jorge E. Cortes, MD, Alessandra Ferrajoli, MD, Steven M. Kornblau, MD, Michael Andreeff, MD, PhD, Min Du, Mark Brandt, Stefan H. Faderl, MD

Blood (2013) 122 (21): 1451.

https://doi.org/10.1182/blood.V122.21.1451.1451

Published: 2013

Journal Articles

Clofarabine Plus Low-Dose Cytarabine Induction Followed By Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine Consolidation In Acute Myeloid Leukemia Frontline Therapy For Older Patients

Aziz Nazha, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Xuelin Huang, Xuemei Wang, MS, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Alessandra Ferrajoli, MD, Marina Konopleva, MD, PhD, Gautam Borthakur, MD, Jan A. Burger, MD, PhD, Jennie Feliu, RN, Stefan H. Faderl, MD

Blood (2013) 122 (21): 3948.

https://doi.org/10.1182/blood.V122.21.3948.3948

Published: 2013

Journal Articles

Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report

Farhad Ravandi, MD, Megan Othus, PhD, Stefan H. Faderl, MD, Derek L. Stirewalt, MD, Sherry R. Pierce, RN, BS, Gautam Borthakur, MD, John Godwin, MD, Jeanne E. Anderson, MD, Stephen Petersdorf, MD, Jorge E. Cortes, MD, Fabiana Ostronoff, MD, Era Pogosova-Agadijanyan, MD, Frederick R. Appelbaum, MD, Hagop M. Kantarjian, MD, Elihu H. Estey, MD

Blood (2013) 122 (21): 2686.

https://doi.org/10.1182/blood.V122.21.2686.2686

Published: 2013

Journal Articles

Clinical Characteristics and Outcomes In Patients With Acute Promyelocytic Leukemia (APL) and Hyperleukocytosis

Naval Daver, MD, Hagop M. Kantarjian, MD, Stefan H. Faderl, MD, Guillermo Garcia-Manero, MD, Susan O'Brien, MD, Alessandra Ferrajoli, MD, Srdan Verstovsek, MD, PhD, Uday Popat, MD, Chitra M Hosing, MD, Tapan M. Kadia, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Paolo Anderlini, MD

Blood (2013) 122 (21): 1343.

https://doi.org/10.1182/blood.V122.21.1343.1343

Published: 2013

NARROW

Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy

Bone Marrow May Be More Informative Than Peripheral Blood To Evaluate Minimal Residual Disease During 1st and 2nd Year Follow Up After First-Line Fludarabine, Cyclophosphamide, and Rituximab For Chronic Lymphocytic Leukemia

Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

Incidence, Clinical Characteristics, and Prognostic Relevance Of Clonal T-Cell Receptor Positive (TCR + ) Populations In Patients With Myelodysplastic Syndrome (MDS)

Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy

Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL)

Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience

A Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, In Patients With Advanced Leukemias

Final Report Of Phase II Study Of Sorafenib and 5-Azacytidine In Patients With Relapsed Or Untreated Acute Myeloid Leukemia and FLT3 -ITD mutation

Incidence Of and Risk Factors For Acute Myeloid Leukemia Involvement Of The Central Nervous System

Signal Transducer and Activator Of Transcription 3 Activates and Deregulates Micro RNA Expression In Chronic Lymphocytic Leukemia Cells

Symptom Burden In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy

Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)

Clofarabine Plus Low-Dose Cytarabine Induction Followed By Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine Consolidation In Acute Myeloid Leukemia Frontline Therapy For Older Patients

Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report

Clinical Characteristics and Outcomes In Patients With Acute Promyelocytic Leukemia (APL) and Hyperleukocytosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only